Primary and metastatic cardiac sarcomas represent rare neoplasms with a variable clinical course. We present a rare case of an 84-year-old man with a cardiac pacemaker and heart osteosarcoma, hepatocellular and prostatic carcinoma, who was admitted with suspected symptoms of infective endocarditis. Findings of cardiac osteosarcoma in a patient with a pacemaker and three malignancies have not been reported before in the literature.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8383708 | PMC |
| http://dx.doi.org/10.14740/jmc3333 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Tumor-derived G-CSF induces an immunosuppressive microenvironment in an osteosarcoma model, reducing response to CAR.GD2 T-cells.
J Hematol Oncol
December 2024
Department of Onco-Haematology and Cell and Gene Therapy, Bambino Gesù Children's Hospital, IRCCS, San Paolo N°15 Street, 00146, Rome, Italy.
Sarcomas are rare, mesenchymal tumors, representing about 10-15% of all childhood cancers. GD2 is a suitable target for chimeric antigen receptor (CAR) T-cell therapy due to its overexpression in several solid tumors. In this preclinical study, we investigated the potential use of iCasp9.
View Article and Find Full Text PDFRare presentation of Ewing's sarcoma underscores the diagnostic challenges in atypical cases.
BMJ Case Rep
December 2024
Era's Lucknow Medical College and Hospital, Lucknow, Uttar Pradesh, India.
Article Synopsis
- A young female patient experienced worsening right-sided chest pain and high-grade fever over 15 days, prompting a medical evaluation.
- Physical exams showed tenderness and reduced air entry in her right lung, leading to imaging that revealed a pleural effusion and a chest wall mass.
- After testing, instead of tuberculosis, the mass was diagnosed as Ewing's sarcoma, atypical for its usual presentation, highlighting the complexities of diagnosing rare conditions in TB-endemic areas.
Importance: The combination of ifosfamide and etoposide (IE) is commonly used to treat relapsed or refractory osteosarcoma; however, second-line treatment recommendations vary across guidelines.
Objective: To evaluate whether the addition of lenvatinib to IE (LEN-IE) improves outcomes in children and young adults with relapsed or refractory osteosarcoma.
Design, Setting, And Participants: The OLIE phase II, open-label, randomized clinical trial was conducted globally across Europe, Asia and the Pacific, and North America.
Pharmacological targeting of P300/CBP reveals EWS::FLI1-mediated senescence evasion in Ewing sarcoma.
Mol Cancer
October 2024
Department of Pediatrics, University of Minnesota, 2231 6th St. SE, Minneapolis, MN 55455, USA.
Article Synopsis
- Ewing sarcoma (ES) is challenging to treat because it's hard to directly target its main driver, EWS::FLI1.
- Researchers found that inhibiting P300/CBP, which is part of the EWS::FLI1 complex, mimics knocking down EWS::FLI1 and can indicate patient outcomes.
- By reversing EWS::FLI1's effects through P300 inhibition, ES cells enter senescence and can be targeted with senolytics that hit the PI3K pathway, suggesting a promising combination therapy for treating ES.
Rapidly Progressive High-Grade Leiomyosarcoma in an Elderly Patient.
Cureus
August 2024
Internal Medicine, Jackson Memorial Hospital, Miami, USA.
Article Synopsis
- An 84-year-old woman with a past medical history of hypertension, diabetes, and hypothyroidism presented with a rapidly growing thigh mass, which was diagnosed as high-grade leiomyosarcoma that doubled in size within two weeks.
- Following surgery and initiation of radiotherapy, she developed complications including respiratory distress and heart failure due to extensive metastatic disease and a pulmonary embolism.
- The case emphasizes the difficulties in treating aggressive sarcomas in frail patients and suggests that earlier intervention with chemotherapy might have led to better outcomes, highlighting the importance of careful patient evaluation for cancer treatment options.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!